Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Short Interest Up 6.4% in November

Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) was the recipient of a large growth in short interest in the month of November. As of November 15th, there was short interest totalling 3,820,000 shares, a growth of 6.4% from the October 31st total of 3,590,000 shares. Based on an average trading volume of 707,100 shares, the days-to-cover ratio is presently 5.4 days. Currently, 6.6% of the shares of the stock are sold short.

Jazz Pharmaceuticals Trading Up 0.9 %

NASDAQ:JAZZ traded up $1.14 on Tuesday, reaching $122.72. 183,778 shares of the company's stock were exchanged, compared to its average volume of 672,367. The firm has a market capitalization of $7.42 billion, a price-to-earnings ratio of 17.12, a price-to-earnings-growth ratio of 1.03 and a beta of 0.57. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The business has a fifty day moving average of $115.13 and a 200-day moving average of $111.21.

Insider Activity at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 3,700 shares of the stock in a transaction on Friday, November 8th. The stock was sold at an average price of $123.41, for a total value of $456,617.00. Following the completion of the transaction, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, November 1st. The stock was sold at an average price of $110.84, for a total transaction of $110,840.00. Following the sale, the chief executive officer now directly owns 428,976 shares in the company, valued at approximately $47,547,699.84. This trade represents a 0.23 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 6,110 shares of company stock valued at $720,160. 4.20% of the stock is owned by company insiders.

Institutional Trading of Jazz Pharmaceuticals

A number of large investors have recently modified their holdings of JAZZ. Swedbank AB purchased a new stake in shares of Jazz Pharmaceuticals in the 2nd quarter valued at approximately $106,936,000. Rubric Capital Management LP purchased a new stake in Jazz Pharmaceuticals during the 2nd quarter worth about $65,812,000. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company's stock valued at $194,346,000 after acquiring an additional 527,187 shares during the last quarter. Baupost Group LLC MA lifted its stake in Jazz Pharmaceuticals by 52.8% during the second quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company's stock worth $136,000,000 after purchasing an additional 440,552 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in Jazz Pharmaceuticals by 1,808.4% during the second quarter. Millennium Management LLC now owns 450,872 shares of the specialty pharmaceutical company's stock worth $48,122,000 after purchasing an additional 427,246 shares during the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Robert W. Baird lifted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an "outperform" rating in a report on Monday, November 18th. Royal Bank of Canada upped their price objective on shares of Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an "outperform" rating in a report on Wednesday, October 23rd. Piper Sandler reaffirmed an "overweight" rating and set a $163.00 target price (down from $166.00) on shares of Jazz Pharmaceuticals in a research note on Thursday, November 21st. Finally, TD Cowen dropped their price target on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a "buy" rating for the company in a research note on Thursday, November 7th. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $175.33.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.